Key result
Endothelin receptor antagonists like bosentan markedly and sustainably improve exercise capacity over placebo in PAH.
Why the study?
Abnormal increases in endothelin-1 production and decreased pulmonary clearance play a major pathogenetic role in pulmonary arterial hypertension, motivating development of endothelin receptor antagonists.
Does bosentan improve exercise capacity in patients with pulmonary arterial hypertension?
Does bosentan improve exercise capacity in patients with pulmonary arterial hypertension?
Endothelin receptor antagonists like bosentan provide sustained improvements in exercise capacity for patients with pulmonary arterial hypertension.
Answers are grounded in this paper and cite their sources.
Supports endothelin pathway targeting in pulmonary hypertension; leaves open optimal patient selection for randomized confirmation.
The endothelin system has been extensively studied over the last several years. It is clear that endothelin-1 (ET-1) is a key mediator in pulmonary vascular biology and physiology. Abnormal increases in ET-1 production and decreased pulmonary clearance appear to play a major pathogenetic and perpetuating role in the pulmonary hypertensive process, through their vasconstrictive, smooth muscle cell proliferative and profibrotic effects. The degree of overexpression of ET-1 may correlate with the severity of pulmonary hypertension (PH). Advances in understanding the role of ET-1 in pulmonary hypertension have driven the development of endothelin receptor antagonists. One such agent, bosentan (Tracleer), is FDA approved for pulmonary arterial hypertension. Bosentan was approved following two randomized, placebo-controlled, double-blind studies that both showed marked improvement in exercise capacity after treatment with bosentan. The beneficial effects of bosentan appear to be sustained in most patients followed for as long as 22 months. Other uses for endothelin receptor antagonists are being examined, such as in combination with epoprostenol (Flolan) or in pediatric PH patients.
No takes yet. Share an insight, caveat, or question.
Channick et al. (2002) conducted a review in Pulmonary Arterial Hypertension. Endothelin receptor antagonists (e.g., bosentan) vs. Placebo was evaluated on Exercise capacity. Endothelin receptor antagonists such as bosentan provide marked and sustained improvement in exercise capacity for patients with pulmonary arterial hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: